STALICLA-SA
11.4.2024 13:01:32 CEST | Business Wire | Press release
STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411118139/en/
Thomas Blaettler, MD, joins STALICLA as Chief Medical Officer. (Photo: Business Wire)
Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights to help progress STALICLA’s ambitions in CNS conditions. He is a board-certified neurologist with 30 years’ experience in neuroscience, both in clinical residency and within the industry (Novartis, BMS, Roche, Orphazyme, Coave Therapeutics, Vectura Fertin Pharma).
As a clinician, he is driven by the desire to advance clinical research for the benefit of patients who are in dire need of better treatments. He has published both preclinical and clinical research articles in top-tier journals such as Nature, Cell, PNAS and Lancet. With time, he has assumed roles with increasing strategic responsibility, overseeing global clinical development programs from Phase 1 to Phase 3.
Thomas has profound regulatory experience across the globe (EMA, FDA, PMDA, CFDA) from pre-IND interaction to submissions of NDAs and MAAs. As Chief Medical Officer at Orphazyme, he established a clinical development and regulatory organization, overseeing four late-stage development programs. In recent years, he was instrumentally involved in two successful IPOs at the Copenhagen and New York Nasdaq stock exchanges. Thomas completed his Doctor of Medicine at the University of Zurich and gained board certification from the Swiss Society of Neurology in 2003.
“We are delighted to welcome Thomas during a pivotal time where his proven track record in navigating clinical and strategic development will support the advancement of STALICLA’s late-stage Phase 2 and 3 clinical pipelines for precision medicine treatment of neurological and neuropsychiatric disorders. His focus on biomarker lead strategies in CNS drug development is an ideal fit with our science and vision to pioneer precision medicine in the neurodevelopmental disorder space.” - Lynn Durham, CEO & Founder.
“I am thrilled to be joining STALICLA, a biotechnical company that is leading the way in future precision medicine in NDDs and other CNS disorders. Moving away from the one size fits all concept in drug development, with modest if at all treatment effects, to tailored treatments that take into account the clinical and pathophysiological heterogeneity of patient populations will revolutionize the way we treat patients.”- Thomas Blaettler, MD.
About STALICLA
STALICLA SA is a Swiss clinical-stage biopharmaceutical company, pioneering precision treatment in neurodevelopmental and neuropsychiatric disorders. With an advanced clinical pipeline of phase 2 and 3 ready assets and an AI-driven precision neuro medicine platform for patient-drug matching, STALICLA is changing the landscape of brain disease treatment. For more information, please visit: https://stalicla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411118139/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Global Photonics Community Converges in San Francisco as More Than 23,000 Register for Photonics West 20263.2.2026 22:14:00 CET | Press release
The largest annual optics and photonics event highlighted the industry’s best and brightest during a week full of innovation, networking, and research sharing SPIE, the international society for optics and photonics, brought the global optics and photonics community to San Francisco, California, for another successful and enlivening Photonics West. With more than 23,000 registrants, the annual conference and exhibition connected attendees from 40 countries, showcasing the transnational and collaborative spirit of the interdisciplinary industry. The dynamic event ran from 17 to 22 January, with 4,200 technical presentations across 100 conferences, 4 stages of industry-focused panels and presentations, 49 courses, and approximately 1,600 exhibitors in the five expos: Photonics West, BiOS, Quantum West, AR | VR | MR, plus, in its inaugural year, Vision Tech. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203925940/en/ Attend
Vena To Acquire Acterys, Creating a New Category of Enterprise Performance Management: Orchestrated Planning3.2.2026 17:00:00 CET | Press release
The acquisition unites finance foresight and IT innovation in the first Microsoft-native Orchestrated Planning environment, helping enterprises plan better and achieve more by turning strategy into aligned execution in real time. Vena, the only complete FP&A platform powered by agentic AI and purpose-built to amplify the Microsoft technology ecosystem, today announced it has entered into a definitive agreement to acquire Managility Pty Ltd, operating as Acterys (“Acterys”), the industry’s leading Power BI–based operational planning and app development platform, subject to customary closing conditions and regulatory approval. This acquisition unlocks a category-defining way for enterprises to combine planning, analytics, and application development within the Microsoft tools they already trust to run their business. By combining Vena’s Excel-native financial planning and analysis (FP&A) capabilities with Acterys’ proprietary Power BI write-back engine and unified analytics within Micros
Volante Technologies named a Leader in Gartner® Magic Quadrant™ for Banking Payment Hub Platforms3.2.2026 16:15:00 CET | Press release
Volante believes its solutions provide complete always-on payment processing support for banks and financial institutions across all tiers Volante Technologies, the global leader in Payments as a Service (PaaS), today announced its recognition as a Leader in the 2026 Gartner® Magic Quadrant™ for Banking Payment Hub Platforms, which evaluates vendors based on Ability to Execute and Completeness of Vision. In Volante’s view, Gartner positioned them as a Leader based on their capacity to support enterprise-scale payment processing in banks and financial institutions across multiple regions, deployment models, and operational environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203149834/en/ This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. As the highest positioned provider in Ability to Execute, Volante believes its AI-pow
Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek3.2.2026 16:00:00 CET | Press release
Toptal, the world’s largest fully remote workforce, has been ranked the #1 most reliable professional services company in America on the America’s Most Reliable Companies 2026 list by Newsweek and Statista. The list ranks top US companies based on trust, dependability, and consistent performance in their industry. In Newsweek’s ranking of 300 companies across all industries, Toptal took 10th place, right behind Bank of America and Oracle, which tied for 9th. As the most reliable professional services organization in America, Toptal, which ranked 11th in absolute rankings across all companies, placed well ahead of companies like Accenture (33), Deloitte (39), and Cognizant (66). The America’s Most Reliable Companies 2026 ranking is based on an independent survey of more than 80,000 evaluations submitted by 2,400 business decision-makers at America’s largest companies, including Apple, Dropbox, Johnson & Johnson, and UPS, making this recognition an especially meaningful indicator of prod
HTEC Research Reveals the Real AI Scaling Challenge: It’s Not the Technology3.2.2026 15:46:00 CET | Press release
Global executive survey finds AI momentum is real—but leadership alignment, capability gaps, and ROI clarity are slowing enterprise impact AI has moved from ambition to action. Every organization is deploying it. Yet for most enterprises, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203951136/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, released Executive Summary: A Cross‑Industry View of the State of AI in 2025, a global research report capturing how senior executives are navigating the next phase of AI transformation—and why scaling value remains elusive. Today, HTEC, a global AI‑first provider of software and hardware design and engineering services, released Executive Summary: A Cross‑Industry View of the State of AI in 2025, a global research report that captures how senior executives are navigating the next phase of AI tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom